Evidence map›Paper›PMID 33781839›Full record

ReviewMolecular and cellular endocrinology2021

Novel roles of the renal angiotensin-converting enzyme.

Jorge F Giani, Luciana C Veiras, Justin Z Y Shen, Ellen A Bernstein, DuoYao Cao, Derick Okwan-Duodu, Zakir Khan, Romer A Gonzalez-Villalobos, Kenneth E Bernstein

Open access · greenAbstract readReview
In one paragraph

Review in Molecular and cellular endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Sanger Sequencing Reveals Novel Variants inMedicina (Kaunas, Lithuania) · 2024
    Article
  7. Article
  8. Beneficial Effects ofNutrients · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Exploring the Impact of ACE Inhibition in Immunity and Disease.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jorge F GianiDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Jorge.Giani@cshs.org.
Luciana C VeirasDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Justin Z Y ShenDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ellen A BernsteinDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
DuoYao CaoDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Derick Okwan-DuoduDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Zakir KhanDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Romer A Gonzalez-VillalobosCardiovascular and Metabolism Discovery, Janssen Research and Development LLC, Boston, MA, USA.
Kenneth E BernsteinDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USJanssen (United States) · US

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
The Role of Inflammation in Cardiovascular DiseaseP01HL129941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2016 to 2020
$12.4M
Training Program in Endocrinology, Diabetes, and MetabolismT32DK007770 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 1999 to 2022
$3.4M
ACE and myeloid cell metabolismR01AI164519 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI KENNETH E BERNSTEIN · 2022 to 2026
$3.1M
The role of angiotensin-converting enzyme in renal inflammation, kidney injury and sodium retention during diabetic nephropathyR01HL142672 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BERNSTEIN, KENNETH E · 2018 to 2021
$1.7M
Maladaptive Inflammation Impairs Collateral Vessel Formation in Sickle Cell DiseaseK99HL141638 · NHLBI · EMORY UNIVERSITY · PI OKWAN-DUODU, DERICK · 2019 to 2020
$210k
NHLBI NIH HHS K99 HL141638NHLBI NIH HHS P01 HL129941NHLBI NIH HHS R01 HL142672NIAID NIH HHS R01 AI164519NIDDK NIH HHS P30 DK063491NIDDK NIH HHS T32 DK007770
6 · The paper itself

Abstract

The observation that all components of the renin angiotensin system (RAS) are expressed in the kidney and the fact that intratubular angiotensin (Ang) II levels greatly exceed the plasma concentration suggest that the synthesis of renal Ang II occurs independently of the circulating RAS. One of the main components of this so-called intrarenal RAS is angiotensin-converting enzyme (ACE). Although the role of ACE in renal disease is demonstrated by the therapeutic effectiveness of ACE inhibitors in treating several conditions, the exact contribution of intrarenal versus systemic ACE in renal disease remains unknown. Using genetically modified mouse models, our group demonstrated that renal ACE plays a key role in the development of several forms of hypertension. Specifically, although ACE is expressed in different cell types within the kidney, its expression in renal proximal tubular cells is essential for the development of high blood pressure. Besides hypertension, ACE is involved in several other renal diseases such as diabetic kidney disease, or acute kidney injury even when blood pressure is normal. In addition, studies suggest that ACE might mediate at least part of its effect through mechanisms that are independent of the Ang I conversion into Ang II and involve other substrates such as N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), Ang-(1-7), and bradykinin, among others. In this review, we summarize the recent advances in understanding the contribution of intrarenal ACE to different pathological conditions and provide insight into the many roles of ACE besides the well-known synthesis of Ang II.

Indexed as

Acute Kidney InjuryAngiotensin IAngiotensin IIAnimalsBlood PressureBradykininDiabetic NephropathiesGene Expression RegulationHumansHypertensionKidneyMiceOligopeptidesPeptide FragmentsPeptidyl-Dipeptidase ARenin-Angiotensin SystemAngiotensin Iangiotensin I (1-7)Angiotensin IIBradykiningoralatideOligopeptidesPeptide FragmentsPeptidyl-Dipeptidase AAngiotensin-converting enzymeKidneyRenin angiotensin system

Identifiers

PMID33781839
PMCPMC8127398
OpenAlexW3143705130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.